Search alternatives:
significant gender » significant concern (Expand Search), significant burden (Expand Search)
gender decrease » greater decrease (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search), step decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
Showing 261 - 280 results of 1,032 for search '(( significant gender decrease ) OR ( significant ((side decrease) OR (teer decrease)) ))', query time: 0.43s Refine Results
  1. 261
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  2. 262
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  3. 263
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  4. 264
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  5. 265
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  6. 266
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  7. 267
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  8. 268
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  9. 269
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  10. 270
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  11. 271
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  12. 272
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  13. 273
    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity

    First Sila-Vitamin D Analogues: Design, Synthesis, Structural Analysis and Biological Activity by Julian Loureiro (20357035)

    Published 2024
    “…These sila-analogues show similar VDR binding and transcriptional activity in comparison with the natural hormone 1,25D<sub>3</sub>, but with significantly less hypercalcemic activity. The new analogues, when combined with chemotherapy, significantly decrease cell proliferation.…”
    Save to List
    Saved in:
  14. 274
    S1 Graphical abstract -

    S1 Graphical abstract - by Aman Goyal (19231397)

    Published 2025
    “…</p><p>Conclusions</p><p>Our analysis showed a significant decrease in mortality from paroxysmal tachycardia since 1999, although there has been a slight increase in recent years. …”
    Save to List
    Saved in:
  15. 275
    Characterization of systolic pulmonary arterial pressure (sPAP) of WT BMP9 in rats.

    Characterization of systolic pulmonary arterial pressure (sPAP) of WT BMP9 in rats. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 276
    Pharmacological characterization of WT BMP9 and A347E variant <i>in vitro</i> and <i>in vivo.</i>

    Pharmacological characterization of WT BMP9 and A347E variant <i>in vitro</i> and <i>in vivo.</i> by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 277
    Summary of cell-based assay EC50 results for WT BMP9 and A347E variant.

    Summary of cell-based assay EC50 results for WT BMP9 and A347E variant. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 278
    Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode.

    Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 279
    Hemodynamic effects of WT BMP9 in rats.

    Hemodynamic effects of WT BMP9 in rats. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 280
    Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode.

    Evaluation of chronic <i>in vivo</i> efficacy in 21 days rat MCT model in prevention mode. by Tobias G. Schips (21799838)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: